Needham & Company Upgrades ResMed (RMD) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Resmed, Inc. (RMD) Tops Q2 EPS by 2c
January 22, 2015 4:12 PM ESTResmed, Inc. (NYSE: RMD) reported Q2 EPS of $0.64, $0.02 better than the analyst estimate of $0.62. Revenue for the quarter came in at $423 million versus the consensus estimate of $408.2 million.
"We are pleased to report strong double-digit revenue growth, demonstrating excellent progress with our new product launches," said Mick Farrell, ResMed's chief executive officer. "We achieved robust commercial performance across all regions, including... More
